Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

1.

The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma.

Baz R, Li L, Kottke-Marchant K, Srkalovic G, McGowan B, Yiannaki E, Karam MA, Faiman B, Jawde RA, Andresen S, Zeldis J, Hussein MA.

Mayo Clin Proc. 2005 Dec;80(12):1568-74.

PMID:
16342649
[PubMed - indexed for MEDLINE]
2.

Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.

Hussein MA, Baz R, Srkalovic G, Agrawal N, Suppiah R, Hsi E, Andresen S, Karam MA, Reed J, Faiman B, Kelly M, Walker E.

Mayo Clin Proc. 2006 Jul;81(7):889-95.

PMID:
16835968
[PubMed - indexed for MEDLINE]
3.

Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.

Zervas K, Dimopoulos MA, Hatzicharissi E, Anagnostopoulos A, Papaioannou M, Mitsouli Ch, Panagiotidis P, Korantzis J, Tzilianos M, Maniatis A; Greek Myeloma Study Group.

Ann Oncol. 2004 Jan;15(1):134-8.

PMID:
14679133
[PubMed - indexed for MEDLINE]
Free Article
4.

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.

Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, Cavalli M, Stanevsky A, Corradini P, Pezzatti S, Patriarca F, Cavo M, Peccatori J, Catalano L, Carella AM, Cafro AM, Siniscalchi A, Crippa C, Petrucci MT, Yehuda DB, Beggiato E, Di Toritto TC, Boccadoro M, Nagler A, Palumbo A.

Blood. 2012 Jan 26;119(4):933-9; quiz 1093. doi: 10.1182/blood-2011-03-344333. Epub 2011 Aug 11.

PMID:
21835953
[PubMed - indexed for MEDLINE]
Free Article
5.

Thromboembolic events with lenalidomide-based therapy for multiple myeloma.

Menon SP, Rajkumar SV, Lacy M, Falco P, Palumbo A.

Cancer. 2008 Apr 1;112(7):1522-8. doi: 10.1002/cncr.23336.

PMID:
18278812
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.

Bagratuni T, Kastritis E, Politou M, Roussou M, Kostouros E, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Kanelias N, Terpos E, Dimopoulos MA.

Am J Hematol. 2013 Sep;88(9):765-70. doi: 10.1002/ajh.23504. Epub 2013 Jul 24.

PMID:
23757261
[PubMed - indexed for MEDLINE]
7.

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV, Morris C, Toor A, Siegel E, Fink L, Tricot G.

Blood. 2001 Sep 1;98(5):1614-5.

PMID:
11520815
[PubMed - indexed for MEDLINE]
Free Article
9.

Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan.

Wu SY, Yeh YM, Chen YP, Su WC, Chen TY.

Ann Hematol. 2012 Nov;91(11):1773-8. doi: 10.1007/s00277-012-1506-2. Epub 2012 Jun 17.

PMID:
22706703
[PubMed - indexed for MEDLINE]
10.

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.

Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, de Vivo A, Testoni N, Nicci C, Terragna C, Grafone T, Perrone G, Ceccolini M, Tura S, Baccarani M; Bologna 2002 study.

Blood. 2005 Jul 1;106(1):35-9. Epub 2005 Mar 10.

PMID:
15761019
[PubMed - indexed for MEDLINE]
Free Article
11.

Thalidomide therapy and deep venous thrombosis in multiple myeloma.

Rajkumar SV.

Mayo Clin Proc. 2005 Dec;80(12):1549-51. No abstract available.

PMID:
16350272
[PubMed - indexed for MEDLINE]
13.

Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.

Cini M, Zamagni E, Valdré L, Palareti G, Patriarca F, Tacchetti P, Legnani C, Catalano L, Masini L, Tosi P, Gozzetti A, Cavo M.

Eur J Haematol. 2010 Jun;84(6):484-92. doi: 10.1111/j.1600-0609.2010.01434.x. Epub 2010 Feb 23.

PMID:
20192986
[PubMed - indexed for MEDLINE]
14.

Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma.

Jo JC, Kang BW, Sym SJ, Lee SS, Jang G, Kim S, Lee DH, Kim SW, Lee JS, Suh C.

Invest New Drugs. 2011 Feb;29(1):175-81. doi: 10.1007/s10637-009-9343-4. Epub 2009 Oct 13.

PMID:
19823768
[PubMed - indexed for MEDLINE]
15.

Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.

Offidani M, Bringhen S, Corvatta L, Falco P, Marconi M, Avonto I, Piersantelli MN, Polloni C, Boccadoro M, Leoni P, Palumbo A.

Eur J Haematol. 2007 Apr;78(4):297-302. Epub 2007 Feb 5.

PMID:
17286608
[PubMed - indexed for MEDLINE]
16.

Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma.

Hassoun H, Reich L, Klimek VM, Dhodapkar M, Cohen A, Kewalramani T, Zimman R, Drake L, Riedel ER, Hedvat CV, Teruya-Feldstein J, Filippa DA, Fleisher M, Nimer SD, Comenzo RL.

Br J Haematol. 2006 Jan;132(2):155-61.

PMID:
16398649
[PubMed - indexed for MEDLINE]
17.

A retrospective cohort study of venous thromboembolism(VTE) in 1035 Japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of thromboprophylaxis with aspirin and warfarin.

Kato A, Takano H, Ichikawa A, Koshino M, Igarashi A, Hattori K, Nagata K.

Thromb Res. 2013 Feb;131(2):140-4. doi: 10.1016/j.thromres.2012.11.014. Epub 2012 Dec 8.

PMID:
23232090
[PubMed - indexed for MEDLINE]
18.

Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.

Dingli D, Rajkumar SV, Nowakowski GS, Gertz MA, Dispenzieri A, Lacy MQ, Hayman S, Fonseca R, Lust JA, Kyle RA, Greipp PR, Witzig TE.

Haematologica. 2005 Dec;90(12):1650-4.

PMID:
16330438
[PubMed - indexed for MEDLINE]
Free Article
19.

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.

Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA, Kyle RA, Witzig TE.

J Clin Oncol. 2002 Nov 1;20(21):4319-23.

PMID:
12409330
[PubMed - indexed for MEDLINE]
20.

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M; GIMEMA Italian Myeloma Network.

Lancet. 2010 Dec 18;376(9758):2075-85. doi: 10.1016/S0140-6736(10)61424-9. Epub 2010 Dec 9. Erratum in: Lancet. 2011 Nov 26;378(9806):1846.

PMID:
21146205
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk